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Abstract
Background: Gene expression studies require appropriate normalization methods. One such method uses
stably expressed reference genes. Since suitable reference genes appear to be unique for each tissue, we have
identified an optimal set of the most stably expressed genes in human blood that can be used for normalization.
Methods: Whole-genome Affymetrix Human 2.0 Plus arrays were examined from 526 samples of males and
females ages 2 to 78, including control subjects and patients with Tourette syndrome, stroke, migraine, muscular
dystrophy, and autism. The top 100 most stably expressed genes with a broad range of expression levels were
identified. To validate the best candidate genes, we performed quantitative RT-PCR on a subset of 10 genes
(TRAP1, DECR1, FPGS, FARP1, MAPRE2, PEX16, GINS2, CRY2, CSNK1G2 and A4GALT), 4 commonly
employed reference genes (GAPDH, ACTB, B2M and HMBS) and PPIB, previously reported to be stably
expressed in blood. Expression stability and ranking analysis were performed using GeNorm and NormFinder
algorithms.
Results: Reference genes were ranked based on their expression stability and the minimum number of genes
needed for nomalization as calculated using GeNorm showed that the fewest, most stably expressed genes
needed for acurate normalization in RNA expression studies of human whole blood is a combination of TRAP1,
FPGS, DECR1 and PPIB. We confirmed the ranking of the best candidate control genes by using an alternative
algorithm (NormFinder).
Conclusion: The reference genes identified in this study are stably expressed in whole blood of humans of both
genders with multiple disease conditions and ages 2 to 78. Importantly, they also have different functions within
cells and thus should be expressed independently of each other. These genes should be useful as normalization
genes for microarray and RT-PCR whole blood studies of human physiology, metabolism and disease.
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Background
Gene expression analysis is widely used to study various
biological processes. Different transcript quantification
methodologies exist, all of which rely on utilization of
proper normalization techniques. Such analysis requires
several variables need to be accounted for, including
amount and quality of RNA, enzymatic efficiencies, and
differences between tissues or cells in overall transcrip-
tional activity. The current, most universally utilized nor-
malization method for PCR and Northern blotting relies
on the use of constitutively expressed endogenous refer-
ence genes, often termed ''house-keeping genes.'' It has
been shown, however, that the expression of such refer-
ence genes can vary significantly between different tissues
or conditions, thus making it impossible to use the same
reference genes for various tissues [1-5]. Moreover, the
identification of appropriate control genes presents a cir-
cular problem, because in order to find suitable genes for
normalization, prior knowledge of their stable gene
expression is needed, which also relies on properly nor-
malized data.
The conventional use of a single gene for normalization
can introduce a significant error in the quantification of
transcript levels [6]. It is recommended that an optimal set
of reference genes be identified for each individual exper-
imental setting or tissue. In this study, we used whole-
genome human microarrays and surveyed the expression
of over 39,500 genes in 526 whole-blood samples from
control subjects and patients with Tourette syndrome,
stroke, migraine, muscular dystrophy, and autism to iden-
tify the best candidate control genes. The 10 best candi-
date control genes, as well as commonly used house-
keeping controls and PPIB, were validated with independ-
ent samples of whole-blood RNA from both patients with
multiple sclerosis (MS) and age- and gender-matched
controls by qRT-PCR. GeNorm was used to identify an
optimal set of the most stably expressed genes for normal-
ization in whole-blood expression studies [6].
Methods
Patients and samples
We used a large cohort of available human Affymetrx
array data that we have generated over the last several
years from previous and on-going studies (Table 1).
Many, but not all, of the subjects included in our analyses
have previously been reported in the following studies:
stroke [7-10], Tourette syndrome [11-13], controls [14-
18], migraine [19], muscular dystrophy [20,21] and
autism [22,23].
RNA Isolation and Quality Control
Whole blood was collected and total RNA was isolated
using PAXgene tubes and kits (Qiagen, Valencia, CA,
USA). RNA samples were examined for concentration and
purity using a Nanodrop ND-1000 spectrophotometer,
and integrity was checked using the Agilent 2100 Bioana-
lyzer. High quality RNA with a RIN number above 8.0 was
used for the qRT-PCR experiment. The RIN number takes
into consideration not only the conventional ratio of 28 S
to 18 S ribosomal RNA, but also additional critical regions
of the entire RNA electrophoregram.
Affymetrix experiments
Affymetrix Human 2.0 Plus arrays (Affymetrix, Santa
Clara, CA, USA), surveying over 54,000 probe-sets, were
used in this study. The 54,000 probe-sets represent over
39,500 potential human genes (Affymetrix Manual). The
standard Affymetrix protocol was followed for the sample
labeling, hybridization, and image scanning [23].
qRT-PCR cDNA synthesis
The cDNA synthesis and real-time PCR was performed at
the Lucy Whittier Molecular and Diagnostic Core Facility
(University of California, Davis, U.S.A.). The following
cDNA synthesis protocol was validated through the Lucy
Whittier Molecular and Diagnostic Core Facility using a
variety of sample types and species. 10 l (750 ng) of tem-
plate RNA per sample, 1 l gDNA WipeOut Buffer, 1 l
RNase-free water was incubated at 42°C for two minutes
and briefly centrifuged. A 1 L aliquot was TaqMan® ana-
lyzed with human GAPDH to confirm all gDNA had been
digested. Then 8 l from the reverse transcription reaction
mix (0.5 l Quantitect Reverse Transcriptase, 2 l 5×
Quantitect RT buffer, 0.5 l RT Primer Mix, 0.5 l 20 pmol
Random Primers, 4.5 l RNase free water) was added to
each well, incubated at 42°C for 40 minutes, inactivated
at 95°C for 3 minutes and briefly centrifuged. Finally, 100
l of water was added to each well and mixed thoroughly.
Selection of TaqMan Assays
TaqMan assays were selected based on several criteria: 1)
only pre-developed and pre-validated gene expression
assays were selected from Applied Biosystems (ABI, Foster
City, CA, U.S.A.), for which the company guarantees
Table 1: Characteristics of subjects who had gene expression 
assessed in whole blood on Affymetrix Human microarrarys.
Diagnosis Patients Controls
n( M / F ) A g e n ( M / F ) A g e
Stroke 108 (76/32) 68 34 (29/5) 51
Tourette 30 (23/7) 14 32 (24/8) 15
Teen Controls N/A 32 (24/8) 11
Migraine 130 (78/52) 13 10 (6/4) 14
Muscular Dystrophy 51 (43/8) 11 5 (4/1) 11
ASD, Develop Delay 84 (72/12) 4 10 (8/2) 4
The numbers of samples (n), the proportion that came from males 
versus females (M/F) and the mean age (Age) of the subjects are 
tabulated for each group. (ASD = Autism Spectrum Disorder)BMC Medical Genomics 2009, 2:49 http://www.biomedcentral.com/1755-8794/2/49
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amplification efficiency over 96%. 2) Only _m1 assays
(spanning exon -exon boundaries) were selected to ensure
no genomic DNA will be amplified. 3) If available, the
assays were preferentially selected to amplify the same tar-
get sequence where the Affymetrix probe-set was located.
4) If a gene selected for qRT-PCR validation was repre-
sented by multiple probe-sets on the Affymetrix array, the
standard deviation (SD) of the expression of all probe-sets
was inspected and if some were found to have a high
standard deviation, their position in the reference
sequence was avoided.
Real-Time TaqMan® PCR
Pre-validated gene expression assays were purchased from
Applied Biosystems. See Table 1 for the Assay and Gene
IDs. An aliquot of the cDNA from a subset of samples was
TaqMan® analyzed with human GAPDH prior to profiling.
TaqMan® analysis was done in duplicate reactions using
the low density array format as described by Osman et al
[24]. This was validated and processed through the Lucy
Whittier Molecular and Diagnostic Core Facility (1). The
samples were placed in a 384 well plate and amplified in
an automated fluorometer (ABI PRISM 7900 HTA FAST,
ABI). ABI's standard amplification conditions were used:
2 min at 50°C, 10 minutes at 95°C, 40 cycles of 15 sec-
onds at 95°C and 60 seconds at 60°C. Fluorescent signals
were obtained during the annealing temperature and Ct
values exported with a threshold of 0.1 and a baseline of
3–10.
Data Analysis
Affymetrix Chips
All 526 arrays were summarized using the GC-RMA algo-
rithm [25]. They were normalized within GeneSpring 7.3
software (Agilent Technologies, Palo Alto, CA) using a
three-step normalization procedure, including data trans-
formation, per chip and per gene normalization (Gene-
Spring Manual).
qRT-PCR GeNorm Analysis
All samples for which the standard deviation (SD) of the
technical duplicates was  1.41 (or higher than 2-fold
change) were considered missing data points and were
not included in the analysis. The GeNorm tool was used
to calculate the internal control genes stability measures
(M) [6]. In short, input data was generated using the com-
parative Ct-method [26], where relative expression levels
were calculated by setting the lowest Ct value of a particu-
lar gene to 1, and the relative expression levels for the
same gene in the rest of the samples were calculated. Then
for every control gene, the pair-wise variation with all
other control genes is estimated in GeNorm as the SD of
the log-transformed expression ratios. The internal con-
trol gene stability measure M is defined as the average
pair-wise variation of a particular control gene with all
other control genes. Stepwise exclusion of the gene with
the highest M value is performed. Because a pair of control
genes is needed to calculate M, the two most stably
expressed genes cannot be ranked any further. The opti-
mal number of control genes for normalization is deter-
mined by calculating the pair-wise variation Vn/Vn+1
between each set of two sequential normalization factors
[6]. Consistent with the Vandesompele recommenda-
tions, the minimum number of genes for which the V was
smaller than 0.15, was used to define the optimal set of
control genes for normalization. A normalization factor is
calculated based on the geometric mean of the optimal set
of control genes.
qRT-PCR NormFinder Analysis
The NormFinder Excel plug-in [27] was used as an alter-
native algorithm to the GeNorm algorithm for ranking the
expression stability of the control genes. It ranks the can-
didate control genes by estimating their expression stabil-
ity while also taking into account the experimental design
(control and disease groups). The input qRT-PCR results
were the linearized quantities (2-Ct). The main differ-
ences between the GeNorm algorithm [6] and the model-
based approach in NormFinder [27] is that the latter takes
into account the inter- and intra-group variation, as well
as the estimation of variances.
Analysis of Variance (ANOVA)
Partek Genomics Suite (St. Louis, MI, USA) was used to
perform an ANOVA using the Diagnosis as fixed and the
Plate as a random factor ( + Diagnosis + Plate + (Diagno-
sis × Plate) + ). The input data were the normalized data
to the geometric average of the optimal set of control
genes (TRAP1, DECR1, PPIB, and HMBS) using the com-
parative Ct method.
Ct Method
The Ct method [28] was used to calculate the normal-
ized calibrated data. TRAP1, identified by GeNorm as one
of the two most stably expressed genes was used as a nor-
malizer. The average of the healthy controls was used as
the calibrator. In short, the Ct value of the normalizer was
subtracted from the Ct value of each sample (Ct). Then
the value of the calibrator was subtracted (Ct) and the
linearized values were calculated (2-(Ct)). A prerequisite
for using this method of analysis is that the normalizer
and the gene of interest have very similar amplification
efficiency. The ABI assays used in this study have been pre-
validated by the company to have over 96% amplification
efficiency.
Results
Patients and samples
Of the 526 samples, the mean ages of the subjects for each
study varied from age 4 (autism study patients and con-BMC Medical Genomics 2009, 2:49 http://www.biomedcentral.com/1755-8794/2/49
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trols) to age 68 (stroke study patients) with a range of 2 to
78 years of age (Table 1). There was a predominance of
males (387) to females (139). Control subjects had no
known medical, surgical, or psychiatric illnesses. Study
subjects had a variety of medical illnesses with varying
pathophysiologies, including neurodevelopmental and
neurological disorders (autism, mental retardation,
Tourette syndrome), stroke (ischemic brain injury), mus-
cular dystrophy (genetic muscle disease), migraine head-
aches, as well as a presumed autoimmune disease,
multiple sclerosis (Table 1).
Selection of Reference Genes from Whole-Genome 
Affymetrix Arrays
Our goal was to identify stably expressed genes with a
broad range of expression levels from our Affymetrix data
on the 526 samples (Table 1). We chose the 20 most sta-
bly expressed genes from each of five intensity intervals (n
= 100 genes): log2-transformed intensity values between
5–6, 6–7, 7–8, 8–9 and 9–10 (Figure 1). For a list of the
most stable genes over all of the expression levels, see
Additional file 1. Based on our selection criteria, these 100
most stably expressed genes covered a wide range of raw
expression values from 32 to 1024. Functional categoriza-
tion using the Database for Annotation and Visualization,
and Integrated Discovery (DAVID, http://
david.abcc.ncifcrf.gov/) showed that 50% of the anno-
tated genes are involved in primary metabolic processes.
For the list of the 100 most stably expressed genes on the
526 microarrays see Additional file 1.
Selection of Candidate Control Genes for Validation by 
qRT-PCR
The set of 100 stably expressed genes on microarrays was
filtered down to probe-sets with available gene annota-
tion, as well as to probe-sets detecting only a single known
gene (Affymetrix annotation *_at). Based on these criteria,
23 probe-sets were identified (data not shown). From
them, 10 candidate genes were selected for validation
with, on average, two genes per intensity interval. These
10 candidate genes included TRAP1, DECR1, FPGS,
FARP1, MAPRE2, PEX16, GINS2, CRY2, CSNK1G2 and
A4GALT. In the validation, we also included four com-
monly employed reference genes, ACTB, GAPDH, B2M
and HMBS. In addition, PPIB was included because it was
previously reported to be stably expressed in blood [3].
Each gene and ABI assay information is presented in Table
2. The average expression values from the Affymetrix array
data of the genes selected for validation by qRT-PCR are
shown in Figure 2. The range of the SDs of the the log2-
transformed intensity values on the microarrays was
between 0.10 and 0.42 for the 10 candidate reference
genes on the microarrays (solid bars, Figure 2). The SDs
for the remainder genes (open bars, B2M, ACTB, GAPDH,
PPIB and HMBS) ranged between 0.47 and 0.72 on the
microarrays (Figure 2). Based on the Affymetrix array data
alone, FARP1 was the most stably expressed. A general
The Average log2- intensity (x-axis) of 39,500 genes from a  total of 526 Affymetrix Human 2.0 Plus microarrays is plotted  against the standard deviation of the log2- intensity (y-axis) of  those genes Figure 1
The Average log2- intensity (x-axis) of 39,500 genes 
from a total of 526 Affymetrix Human 2.0 Plus micro-
arrays is plotted against the standard deviation of the 
log2- intensity (y-axis) of those genes. Probe-sets high-
lighted in red are the 100 probe-sets with the lowest stand-
ard deviation within an interval of the log2-transformed 
intensity values between 5 and 10.
Average expression calculated from the 526 Affymetrix  Human 2.0 Plus microarrays for the candidate control genes  selected for qRT-PCR validation Figure 2
Average expression calculated from the 526 Affyme-
trix Human 2.0 Plus microarrays for the candidate 
control genes selected for qRT-PCR validation. Aver-
age of the log2-transformed intensity values ± standard devia-
tion (y-axis) is plotted for each gene. Gray columns represent 
the candidate control genes selected from Figure 1. White 
columns represent commonly used house-keeping genes and 
PPIB.BMC Medical Genomics 2009, 2:49 http://www.biomedcentral.com/1755-8794/2/49
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trend of increasing SD with increasing intensity was noted
for the candidate reference genes (Figure 2).
qRT-PCR Analysis and Expression of Candidate Control 
Genes
The analysis flowchart presented in Figure 3 describes the
steps used to analyze the qRT-PCR data. The subset of 15
candidate reference genes (Table 2), validated on qRT-
PCR, exhibited a broad range of expression levels from
17.93 to 36.66 cycle threshold (Ct) values (Table 3, Figure
4). Samples for which the SD on the technical replicates
was higher than 1.4 (a fold-change higher than 2) were
considered unreliable data and were not included in the
downstream analysis, thus reducing the sample size for
some assays to lower than 40 (Table 3). Genes that had SD
 1.0 on the average raw Ct values of all samples were con-
sidered to be stably expressed. Based on that criteria,
TRAP1, B2M, DECR1, PPIB, FPGS, HMBS and FARP1
(Table 3, Figure 4, below the dotted line) showed stable
expression over all 40 samples. In contrast, MAPRE2,
PEX16, GINS2, ACTB, GAPDH, CRY2, CSNK1G2 and
A4GALT did not show stable expression over the samples
(Table 3, Figure 4 above the dotted line). The stably
expressed genes covered a wide range of expression levels,
from a high level of expression of 17.9 Ct for B2M, to low
levels of 35.71 Ct for FARP1 (Table 3, Figure 4).
Expression Stability and Ranking Analysis
To identify the most suitable set of genes for normaliza-
tion in whole-blood, the average expression stability (M)
for those reference genes which showed SD of raw Ct-val-
ues  1.0 on all samples was calculated using the GeNorm
tool (see Methods). Those genes included TRAP1, FPGS,
B2M, DECR1, PPIB and HMBS (Figure 4). All of these
genes also had a SD of the Ct-values for the technical
duplicates of  1.41 and a SD of the raw Ct values of all
samples  1.0. The FARP1 gene was omitted from the
analysis of the expression stability because GeNorm does
not allow missing values. However, re-analysis where
FARP1 was included with the rest of the five stably
expressed genes (with n = 35) did not change the final
results (data not shown).
An important pre-requisite for estimating the Expression
Stability Measure is that the genes are not coordinately
regulated. The Gene Ontology terms of the six genes, ana-
lyzed in GeNorm, are presented in Table 4. These genes
are involved in different biological process, molecular
functions and/or are located in different cellular compart-
ments.
The GeNorm algorithm calculates the M value of a gene
based on the average pair-wise variation between all genes
in the analysis. Figure 5A plots the average expression sta-
bility of the six reference genes. This curve was generated
by a step-wise exclusion of the least stable reference gene.
It shows that B2M was the least stable, while TRAP1 and
FPGS were the two most stably expressed genes in whole
blood of patients with MS and gender and age matched
controls.
Determination of the optimal number of reference genes
for normalization of the dataset uses a metric called V. It
is the pair-wise variation of two sequential normalization
factors. For consistency with the recommendations of
Vandesompele et al [6], the least number of genes for
which V<0.15 should be selected as the optimal set of
genes for normalization. In the study, the four most stably
expressed genes, TRAP1, FPGS, DECR1 and PPIB, repre-
sent the optimal set of genes for normalization (Figure
5B). We estimated the gene expression stability and rank-
ing of the control genes using an alternative algorithm
Table 2: The panel of candidate reference genes chosen for validation by qRT-PCR.
Gene Symbol ABI Assay ID GenBank ID Gene Name
FARP1 Hs01120587_m1 BF213279 FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 (chondrocyte-derived)
CRY2 Hs00901393_m1 AB014558 cryptochrome 2 (photolyase-like)
FPGS Hs00191956_m1 NM_004957 folylpolyglutamate synthase
A4GALT Hs00213726_m1 NM_017436 alpha 1,4-galactosyltransferase
TRAP1 Hs00972326_m1 NM_016292 heat shock protein 75
GINS2 Hs00211479_m1 AW205303 DNA replication complex GINS protein PSF2
PEX16 Hs00937316_m1 AA523441 peroxisomal biogenesis factor 16
CSNK1G2 Hs00176258_m1 AL530441 casein kinase 1, gamma 2
DECR1 Hs00154728_m1 NM_001359 2,4-dienoyl CoA reductase 1, mitochondrial
MAPRE2 Hs00183921_m1 NM_014268 microtubule-associated protein, RP/EB family, member 2
PPIB Hs00168719_m1 NM_000942 peptidylpropyl isomerase B
HMBS Hs00609297_m1 NM_000190 hydroxymethyl-bilane synthase
ACTB Hs00242273_m1 NM_001615 beta-actin
B2M Hs99999907_m1 NM_004048 beta-2-microglobulin
GAPDH Hs99999905_m1 NM_002046 glyceraldehyde-3-phosphate dehydrogenaseBMC Medical Genomics 2009, 2:49 http://www.biomedcentral.com/1755-8794/2/49
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Flow chart of the data analysis performed for the qRT-PCR studies Figure 3
Flow chart of the data analysis performed for the qRT-PCR studies.
Expression (average raw Ct, x axis) is plotted versus Standard Deviation of average raw Ct (y axis) for all of the candidate con- trol genes Figure 4
Expression (average raw Ct, x axis) is plotted versus Standard Deviation of average raw Ct (y axis) for all of 
the candidate control genes. qRT-PCR was performed on RNA samples from 20 multiple sclerosis (MS) patients and 20 
age and gender matched controls. The average expression and its standard deviation was calculated for each gene for all of the 
patients combined (n = 40). (Ct = Cycle threshold).BMC Medical Genomics 2009, 2:49 http://www.biomedcentral.com/1755-8794/2/49
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(NormFinder). The relative ranking of the genes was
essentially the same as the one obtained using GeNorm.
The most stable gene was TRAP1 (stability value 0.066),
followed by FPGS (0.067), DECR1 (0.078), PPIB (0.079),
HMBS (0.095) and B2M (0.108). The main differences
between the GeNorm algorithm (reference) and the
model-based variance estimation approach in
NormFinder [27] is that the latter takes into account the
inter- and intra-group variation and uses direct estimation
of variances as opposed to pair-wise variation.
Analysis of Variance (ANOVA)
To identify genes that showed differential expression
between the MS subjects and the healthy controls, an
ANOVA was performed on the qRT-PCR data. Diagnosis
and each PCR-plate were included as factors. CSNK1G2
showed significant differences in expression between MS
and control samples (Table 5, p < 0.05). However, if mul-
tiple-comparison correction is applied to this p-value, it is
not statistically significant. Expression of the remaining
genes did not differ significantly between the matched
pairs (Table 5). No significant p-values (p  0.05) for
plate, nor for the Diagnosis-versus-plate interaction were
found, suggesting no significant technical bias in the
study (data not shown). The fold-change of expression
between the MS and the healthy controls for the stably
expressed genes (Figure 4, below the dotted line) was clos-
est to 1.0 for FPGS (Table 5). ACTB and A4GALT fold-
changes could not be estimated in Partek due to multiple
missing values. The greatest deviation from the 1.0 ratio
for all the genes was observed for CSNK1G2. We also used
the Ct method [28], as described in the Methods sec-
tion, to calculate fold-change. B2M showed the smallest
deviation from the 1.0 ratio for the most stably expressed
genes (Table 5). TRAP1, identified by GeNorm as one of
the most stably expressed genes, was used as the Normal-
izer; therefore, its ratio is not relevant. The highest devia-
tion from the 1.0 ratio for all the genes was observed for
CSNK1G2, as expected.
Data on the four genes, which constitute the optimal set
of normalizers (TRAP1, FPGS, DECR1 and PPIB) on the
MS and healthy control samples are shown separately as
box-and-whisker plots (Figure 6). Data for both the Ct
and Comparative Ct methods for MS versus control
patients are shown in Table 5, with similar results being
obtained with both methods.
Discussion
Gene expression techniques such as qRT-PCR, microar-
rays and Northern blotting require accurate normaliza-
tion methods in order to obtain reliable, quantitative
data. A common approach is to use an endogenous refer-
ence gene. The purpose of the reference gene(s) is to
remove differences not attributable to real biological var-
iation. However, numerous reports indicate that differ-
ences in the expression levels of commonly used
endogenous reference genes vary considerably between
different tissues and between different experimental con-
ditions. Thus, there are no universal reference genes for all
tissues or experimental conditions [2,3,29-35].
To address this problem, the best reference genes must be
determined for each individual tissue or experimental set-
ting. Moreover, a combination of several endogenous
control genes produces more reliable normalization than
any single control gene [6]. We therefore examined the
expression of over 39,000 genes in 526 samples of whole
blood from men, women and children that included
healthy controls and individuals with a variety of different
diseases. The 100 most stably expressed probe-sets were
identified based upon having the least variance across all
of these samples over a broad range of expression values.
These 100 genes could also be useful as endogenous inter-
nal controls for microarray studies – an approach not
commonly used at present for microarray studies. Fifty
percent of the annotated genes were involved in primary
metabolic processes. Thus these genes appear to be good
''housekeeping genes'' for human blood because of their
stable expression across various ages, genders, and dis-
eases.
qRT-PCR validation was then performed on 10 candidate
reference genes, four commonly used reference genes
(ACTB, GAPDH, B2M, and HMBS) and PPIB, which is
Table 3: qRT-PCR on multiple sclerosis patients and normal 
controls
Gene Name Ct-avg SD CV n
TRAP1 25.72 0.62 0.024 40
B2M 17.93 0.78 0.044 40
DECR1 25.72 0.79 0.031 40
PPIB 24.67 0.82 0.033 40
FPGS 27.88 0.84 0.030 40
HMBS 29.02 0.94 0.032 40
FARP1 35.79 0.98 0.027 35
MAPRE2 27.39 1.01 0.037 40
PEX16 27.95 1.09 0.039 40
GINS2 32.42 1.10 0.034 40
ACTB 36.66 1.11 0.030 23
GAPDH 22.07 1.32 0.060 40
CRY2 29.73 1.37 0.046 40
CSNK1G2 28.64 1.49 0.052 40
A4GALT 34.92 1.69 0.048 32
Average raw Cycle threshold values (Ct-avg), standard deviation (SD), 
coefficient of variability (CV) and sample size (n) for the qRT-PCR 
analyses of RNA samples from 20 patients with multiple sclerosis 
compared to 20 age and gender matched control subjects. Because 
those samples that had a SD > 1.41 for the duplicates were excluded 
from the analysis, the sample size is less than 40 for some of the 
genes.BMC Medical Genomics 2009, 2:49 http://www.biomedcentral.com/1755-8794/2/49
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reported to be stably expressed in blood [3]. The two fre-
quently used control reference genes in nervous tissue,
ACTB and GAPDH, were not stably expressed under our
experimental conditions and are therefore not suitable
reference genes for human whole blood. They have also
been shown to vary in a variety of experimental settings
and tissues [2,33,36-39], including in whole blood [3].
B2M and PPIB showed stable expression in our study.
They were not identified as stably expressed in our
Affymetrix data because their expression was higher than
our upper limit for selection. PPIB was also reported to be
stably expressed in whole blood of patients with local and
systemic inflammatory syndromes and healthy controls
[3]. HMBS had a high SD based on our Affymetrix arrays
on the 526 samples (SD of log-2-transformed values =
0.72). For comparison, the most stably expressed genes in
the same intensity interval had a standard deviation (SD)
of the log-2-transformed values around 0.2. HMBS, how-
ever, showed stable expression when using qRT-PCR in
the MS versus healthy controls experiment. Closer inspec-
tion of the expression stability on the 526 samples from
the Affymetrix chips showed that the HMBS SD of the log-
Table 4: Gene Ontology (GO) Annotation of genes analyzed in GeNorm
Gene Symbol Gene Name GO Biological Process 
Term
GO Molecular Function 
Term
GO Cellular Component
Term
FPGS folylpolyglutamate synthase nucleobase, nucleoside,
nucleotide and nucleic acid
metabolic process
glycine metabolic process
one-carbon compound 
metabolic
process
biosynthetic process
nucleoside metabolic
process
folic acid and derivative
biosynthetic process
nucleotide binding
Tetrahydrofolylpoly-
glutamate-synthase activity
ATP binding
ligase activity
cytoplasm
mitochondrion
cytosol
TRAP1 TNF receptor-associated 
protein 1
protein folding nucleotide binding
receptor activity
tumor necrosis factor
receptor binding
ATP binding
unfolded protein binding
Mitochondrion
DECR1 2,4-dienoyl CoA reductase 1, 
mitochondrial
metabolic process
oxidation reduction
catalytic activity
Binding
2,4-dienoyl-CoA
reductase(NADPH)
activity
oxidoreductase activity
mitochondrion
PPIB peptidylprolyl isomerase B 
(cyclophilin B)
protein folding peptidyl-prolyl cis-trans
isomerase activity
protein binding
isomerase activity
peptide binding
unfolded protein binding
endoplasmic reticulum
endoplasmic reticulum
lumen
melanosome
HMBS hydroxymethyl-bilane 
synthase
porphyrin biosynthetic process
heme biosynthetic process
tetrapyrrole biosynthetic 
process
hydroxymethylbilane synthase 
activity
transferase activity
cytoplasm
B2M beta-2-microglobulin antigen processing and 
presentation of peptide antigen 
via MHC class I
immune response
protein binding Golgi membrane
extracellular region
plasma membrane
early endosome
membrane
MHC class I protein complexBMC Medical Genomics 2009, 2:49 http://www.biomedcentral.com/1755-8794/2/49
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2-transformed values for most of the studies was around
0.5, but it was 0.94 for the stroke study. This result sug-
gests that there were study-specific differences for stroke
versus the other diseases, leading to its unstable expres-
sion. Our conclusion that HMBS was unstably expressed
across our 526 samples is consistent with a previous study
reporting that HMBS was unstably expressed in leukocytes
[6]. Among the 10 candidate reference genes, TRAP1,
DECR1, FPGS, and FARP1 showed the most stable expres-
sion.
In most research studies, the target genes or genes regu-
lated within the study are expressed at different levels. In
such situations, it is preferable if the comparable endog-
enous or "housekeeping genes" are expressed at compara-
ble levels as the target gene. This is essential if the
microarray, RT-PCR or Northern blotting platform is non-
Identification of the most stably expressed reference genes using GeNorm analysis Figure 5
Identification of the most stably expressed reference genes using GeNorm analysis. RNA samples from whole-
blood from 20 MS patients and 20 matched controls were analyzed using qRT-PCR. A. Average expression stability values (M) 
of the reference genes during step-wise exclusion of the least stable control gene. The x- axis shows the gene with the highest 
M value (the lowest stability) for this set of genes. The least stable gene was excluded after each iteration. B. Determination 
ofthe optimal number of reference genes for normalization. V is the pair-wise variation of two sequential normalization factors. 
The least number of genes for each V<0.15 was selected as the optimal set of genes for normalization [6]. In this study, the 
four most stably expressed genes (TRAP1, FPGS, DECR1 and PPIB) represent the optimal set of genes for normalization.BMC Medical Genomics 2009, 2:49 http://www.biomedcentral.com/1755-8794/2/49
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Table 5: Diagnosis effect on the candidate control genes.
Ct Method Comparative Ct Method
Normalized to TRAP1 Normalized to Optimal Set of 4 Genes*
Gene Fold Change (MS/H) Fold Change (MS/H) p-value(Diagnosis)
FPGS 1.08 1.00 0.964
ACTb 1.08 ND 0.788
GINS2 1.21 1.11 0.691
HMBS 1.12 1.06 0.581
B2M -1.04 -1.10 0.575
FARP1 1.34 1.16 0.559
A4GALT -1.01 ND 0.416
TRAP1 ** -1.08 0.342
GAPDH -1.45 -1.61 0.198
DECR1 -1.09 -1.11 0.161
PPIB 1.32 1.22 0.155
PEX16 1.32 1.23 0.073
MAPRE2 1.42 1.30 0.072
CRY2 1.58 1.45 0.065
CSNK1G2 1.76 1.63 0.026
Expression of the candidate reference genes in whole blood of multiple sclerosis (MS) subjects is compared to age and gender matched control 
subjects using the Ct Method and the Comparative Ct Method. Genes are arranged in the order of decreasing p-value for diagnosis.
*ANOVA:  + Diagnosis + Plate + (Diagnosis × Plate) + 
**TRAP1 fold change not calculated since that gene was used as a normalizer.
RNA expression values are shown for the four most stably expressed genes (TRAP1, FPGS, DECR1 and PPIB) for multiple  sclerosis (MS) and controls subjects Figure 6
RNA expression values are shown for the four most stably expressed genes (TRAP1, FPGS, DECR1 and PPIB) 
for multiple sclerosis (MS) and controls subjects. Circles represent individual qRT-PCR Ct average raw values for MS 
samples (blue, n = 20) and age and gender matched controls (red, n = 20). Boxes represent the 25th and 75th quartile and lines 
represent the median. Whiskers represent the range of data for the 10th and 90th quartile.BMC Medical Genomics 2009, 2:49 http://www.biomedcentral.com/1755-8794/2/49
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linear at very low or at very high levels. Thus, having a set
of endogenous reference genes that are stably expressed at
different levels makes it possible to help select those
whose expression is comparable to the target genes.
An optimal set of reference genes was identified based on
the expression stability measure M as utilized in the
GeNorm algorithm. It is based on the concept that the
ratio between two ideal reference genes should always be
constant regardless of the experimental conditions used.
An important assumption here is that the genes in the
analysis are not coordinately regulated and have inde-
pendent functions. The six genes analyzed in GeNorm,
seem to be involved in different biological processes,
molecular functions and/or are located in different cellu-
lar compartments (Table 4). TRAP1 and PPIB are involved
in the same biological process however their cellular com-
partmentalization is different. TRAP1 is a mitochondrial
molecular chaperone also known as heat shock protein 75
(Hsp75). PPIB, encoding the cyclophillin B protein, is a
cytoplasmic peptide isomerase. The broad spectrum of
functions of the stably expressed genes makes it less likely
that they are coordinately regulated.
An advantage of the approach taken in this study is that
we performed a whole-genome survey of a large number
of subjects of different ages, genders and diseases to iden-
tify the most stably expressed genes in whole blood.
Drawbacks to this approach include the fact that it is an
array-based discovery method that is less likely to reliably
detect very low expressing genes. In addition, the subjects
chosen do reflect some bias related to the diseases studied,
and reflect other biases in the subject selection – such as
predominantly hospitalied and male patients.
It should be emphasized that the ultimate usefulness of
the proposed endogenous reference genes for whole
blood has not been demonstrated in this study. To do this,
future studies must show that after correcting technical
and individual variability according to the control genes,
the discriminatory power of the diagnostic genes should
be substantially improved.
It is important to point out the utility of the reference
genes identified here for use in clinical human testing.
Should the reference genes identified in this study provide
sufficiently accurate normalization, then genes of interest
could be normalized to these reference genes in healthy
individuals and in individuals with a given disease or
physiological condition. Once reference expression levels
and standard deviations are derived in a large group of
healthy individuals, deviations could be identified in tar-
get individuals using these endogenous genes for normal-
ization without the need for repeated samples from
normal, healthy individuals. For non-clinical research
studies, such normalization to the same endogenous ref-
erence genes would allow for comparison across studies.
Conclusion
We took advantage of the large amount of expression data
on 33,000 genes from 526 individuals to select genes that
had stable expression in whole blood. This gave us an
added advantage to assess not only the gene expression of
commonly used housekeeping genes but to perform a
whole genome survey for stably expressed genes over mul-
tiple ages, disease conditions and different expression lev-
els. Ranking based on the expression stability from qRT-
PCR data of the candidate control genes and estimation of
the minimum number of genes needed for nomalization
showed that the fewest, most stably expressed genes
needed for acurate normalization in RNA expression stud-
ies of human whole blood is a combination of TRAP1,
FPGS, DECR1 and PPIB. These genes should be useful as
normalization genes for a wide-range of whole blood
expression studies in humans.
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